Physician profile
Deepti Gupta
NPI 1619936069
$3,414.39
in general payments reported to CMS, 2019-2025
24 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $130 · 2021: $297 · 2022: $519 · 2023: $737 · 2024: $492 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,274.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $684.09 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $530.74 | 2019-2025 | |
| Lilly USA, LLC | $464.56 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $365.61 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $277.18 | 2019-2025 | Wegovy |
| Abbvie INC. | $234.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $140.79 | 2020-2023 | |
| Esperion Therapeutics, INC. | $108.82 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $106.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $94.24 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Corcept Therapeutics | $69.19 | 2025 | Korlym |
| Astellas Pharma US INC | $46.49 | 2023 | Veozah |
| Abbott Laboratories | $46.39 | 2022-2023 | Freestyle Libre 3 |
| Endo Pharmaceuticals INC. | $39.65 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.63 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.49 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $20.56 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $20.39 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2024 | Dupixent |
| Lundbeck LLC | $18.59 | 2025 | Rexulti |
| Genentech USA, INC. | $17.02 | 2019 | |
| Inspire Medical Systems, INC. | $15.80 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $13.64 | 2022 | |
| Almatica Pharma LLC | $12.89 | 2023 | Gralise, Sertraline Hcl, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepti Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.